이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume

2017년 12월 11일 업데이트: Johanna Savilampi, Region Örebro County

Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume: a Randomized, Double-Blind Study in Healthy Volunteers

The purpose of the study is to evaluate the impact of different bolus volumes and viscosity on remifentanil-induced swallowing dysfunction in healthy volunteers.Hence, whether swallowing tasks can be done safer during sedation by altering bolus volumes and viscosities will be revealed. Furthermore, the study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. If methylnaltrexone reverses the remifentanil-induced effects on swallowing, this would suggest a dominant peripherally mediated mechanism.

연구 개요

상세 설명

Monitored anesthesia care (MAC) is commonly applied in modern perioperative care and means that minor surgical procedures are accomplished in awake patients using local anesthesia and light sedation. MAC has many advantages compared to general anesthesia; the recovery time after anesthesia is shorter and risk for postoperative nausea is lower to mention some. However, the patient is spontaneously breathing and the airway is not protected by an endotracheal tube which potentially increases risk of pulmonary aspiration. Pulmonary aspiration, that is inhalation of stomach and/or pharyngeal contents into the lungs, is a severe anesthesia-related complication and can in worst case lead to pneumonia and even death. Intact swallowing function is crucial in avoiding aspiration and how sedatives and analgesic agents used during MAC influence swallowing function is not fully understood.

Pharyngeal function during bolus swallowing is measured by combined high resolution impedance manometry (HRIM). The HRIM catheter is inserted through the nose in such a way that sensors straddle the entire pharynx and esophagus with the distal catheter tip in the stomach. Dynamic pressure changes and flow can be detected during swallowing and data registered by HRIM are analysed using purpose-designed software, AIM analysis (automated impedance manometry analysis). AIM analysis derives pressure flow variables which describe different physiological events like bolus timing and bolus distension in the pharynx and the esophagus during swallowing. A Swallow Risk Index value, quantifying risk of deglutitive aspiration, can also be defined.

The aim of the study is to evaluate impact of different bolus volumes on remifentanil-induced swallowing dysfunction in healthy volunteers. The study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. Furthermore, whether swallowing tasks can be done safer during sedation by altering bolus volumes will be revealed. In addition to bolus volume, different bolus viscosities will be tested. It is shown that higher bolus viscosity diminishes misdirected swallows in dysphagic patients and higher bolus viscosity may possibly counteracts the swallowing dysfunction induced by remifentanil. Moreover, if MNTX reverses the remifentanil-induced effects on swallowing, then this would suggest a dominant peripherally mediated mechanism. Our aim is also to evaluate impact of remifentanil exposure on esophageal motility and impact of methylnaltrexone alone on swallowing function.

20 healthy volunteers will be studied on two different occasions approximately one week apart. In a randomized order volunteers will receive intravenous infusion of remifentanil and an intravenous injection of MNTX on one occasion, and placebo (normal saline) infusion and an intravenous injection of MNTX on the other occasion. Blood samples are obtained for plasma concentration determination of the study drug and sedation levels are assessed during study drug exposure.

연구 유형

중재적

등록 (예상)

20

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. ≥ 18 - ≤ 40 year old healthy volunteers from both sexes.
  2. Have signed and dated Informed Consent.
  3. Willing and able to comply with the protocol for the duration of the trial.

Exclusion Criteria:

  1. Anamnesis of pharyngoesophageal dysfunction.
  2. Known or history of gastrointestinal, severe cardiac, pulmonary or neurological disease
  3. Ongoing medication that may affect upper gastrointestinal tract, larynx or lower airway.
  4. Allergies to or history of reaction to remifentanil, fentanyl analogues or dexmedetomidine.
  5. Pregnancy or breast feeding
  6. BMI > 30
  7. Smoking
  8. Previous participation in a medicinal clinical trial during the last year where an opioid has been used or have during the last 30 days participated in any other medicinal clinical trial or in a trial where follow-up is not completed.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: RemifentanilMNTX
Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
다른 이름들:
  • 울티바
  • 리리스터
  • 레미펜타닐
  • 메틸날트렉손
활성 비교기: PlaceboMNTX
Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
다른 이름들:
  • 염화나트륨 0.9%
  • 리리스터
  • 메틸날트렉손

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pressure Flow pharyngeal variables, 10 ml vs 20 ml bolus
기간: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure between bolus volumes of 10 ml and 20 ml compared to placebo.
Up to 60 minutes

2차 결과 측정

결과 측정
측정값 설명
기간
Pressure Flow pharyngeal variables, liquid vs semisolid bolus
기간: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure between liquid and semisolid boluses compared to placebo
Up to 60 minutes
Pressure Flow pharyngeal variables, remifentanil before vs after methylnaltrexone
기간: Up to 60 minutes
Difference in pharyngeal pressure flow variables during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Up to 60 minutes
Pressure Flow pharyngeal variables, placebo before vs after methylnaltrexone
기간: Up to 60 minutes
Difference in pharyngeal pressure flow variables during placebo infusion before and after methylnaltrexone administration.
Up to 60 minutes
Pressure Flow esophageal motility variables, 10 ml vs 20 ml bolus
기간: Up to 60 minutes
Difference in variables of esophageal motility between different bolus volumes during remifentanil exposure compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, liquid vs semisolid bolus
기간: Up to 60 minutes
Difference in variables of esophageal motility between liquid and semisolid boluses during remifentanil exposure compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, remifentanil before vs after methylnaltrexone
기간: Up to 60 minutes
Difference in variables of esophageal motility during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
Up to 60 minutes
Pressure Flow esophageal motility variables, placebo before vs after methylnaltrexone
기간: Up to 60 minutes
Difference in variables of esophageal motility during placebo infusion before and after methylnaltrexone administration.
Up to 60 minutes

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Johanna Savilampi, MD, PhD, University Hospital in Örebro

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2017년 11월 11일

기본 완료 (예상)

2018년 4월 1일

연구 완료 (예상)

2018년 4월 1일

연구 등록 날짜

최초 제출

2017년 9월 12일

QC 기준을 충족하는 최초 제출

2017년 9월 12일

처음 게시됨 (실제)

2017년 9월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2017년 12월 12일

QC 기준을 충족하는 마지막 업데이트 제출

2017년 12월 11일

마지막으로 확인됨

2017년 12월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

인두 기능 장애에 대한 임상 시험

구독하다